Contributing Editors

1. IT/OT Convergence Could Lighten Biopharma's Automation Burden 11/9/2026

   Integration lets frameworks talk to each other through middleware. Convergence brings them under the same architecture, which can can reduce costs and maintenance.

2. How Peptides Are Expanding The Possibilities Of Drug Discovery 11/9/2026

   GLP-1 therapies demonstrate the impact peptide medicines have. The opportunity ahead is to extend that impact across a much broader range of biology and achieve new ways to intervene.

3. The 2026 Pharma R&D AI Sourcing Map: Partnerships, Concentration, Inflection 11/9/2026

   A Beroe analysis of 2026 pharma AI deals shows discovery still dominates, suppliers are consolidating, and clinical development is the next AI sourcing frontier.

4. Beyond The Plate Count: How To Build A Defensible Environmental Monitoring Trend Review 11/6/2026

   Determining whether a drug manufacturing environment is stable, drifting, or developing a recurring loss-of-control signal requires integrated trend evaluation.

5. What Europe's Draft Annex 22 Actually Asks Of Human Oversight Of AI 11/4/2026

   The European Commission and the Pharmaceutical Inspection Co-operation Scheme (PIC/S) consulted on draft Annex 22, Artificial Intelligence. Here's what you should know.

6. How To Keep Your 'Big Bang' Platform Switch From Becoming A Big Bust 11/4/2026

   Leaders at a Roche fill/finish facility describe the tactile steps involve to change EMS, ERP, and WMS all at once with no rollback option.

7. FDA Rethinks Skin Sensitization Testing For Generic Transdermal And Topical Delivery Systems 11/3/2026

   The FDA has released a new draft guidance, Assessing the Irritation and Sensitization Potential of Transdermal and Topical Delivery Systems for ANDAs. The document is set to replace the 2023 version.

8. How Is Your Glass Supplier Adapting To Europe's Energy Crisis? 11/3/2026

   Europe's glass manufacturers, including those making pharmaceutical lab glassware, have experienced a series of energy shocks. Many have adopted sustainability practices.

9. The EU Overhauls Pharma Laws: What You Need To Know 11/2/2026

   On Sept. 18, the Council of the EU published the almost-final text of a major overhaul of the EU pharmaceutical laws. The final binding text is expected to be published very soon.

10. September 2026 — CDMO Opportunities And Threats Report 10/28/2026

    Each month, Outsourced Pharma works in conjunction with PharmSource, part of GlobalData, to present its “Contract Manufacturing: Opportunities and Threats (CMOT) Report” to our readers. The report identifies CDMOs that might be impacted by key events affecting their clients, including company acquisitions, product acquisitions and licenses, product approvals, late clinical product terminations, and FDA rejections.